On this website patients and their relatives can find all relevant information on ovarian cancer and the research programme GANNET53 which is funded by the European Union. The aim of GANNET53 is to find an efficient new therapy for patients whose ovarian cancer has returned after primary therapy of the disease, and has become resistant to platinum-containing standard chemotherapy.

Please note that currently no further patients will be included in the GANNTE53 clinical trial. We are planning to carry out a follow-up trial. Further information will follow soon on this website.